Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

114 results about "BRD4" patented technology

Bromodomain-containing protein 4 is a protein that in humans is encoded by the BRD4 gene. BRD4 is a member of the BET (bromodomain and extra terminal domain) family, which also includes BRD2, BRD3, and BRDT. BRD4, similar to other BET family members, contains two bromodomains that recognize acetylated lysine residues. BRD4 also has an extended C-terminal domain with little sequence homology to other BET family members.

BRD4 protein degradation agent compound as well as preparation method and application thereof

The invention provides a compound as shown in a formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, a nitrogen oxide, a solvate, a polymorphic substance, a metabolite, ester, a prodrug or pharmaceutically acceptable salt thereof, which have better BRD4 inhibition and degradation effects as a drug, and can be used for preparing drugs related to BRD4 inhibition and degradation. And preventing and / or treating related diseases. # imgabs0 #
Owner:MIRACURE BIOTECHNOLOGY LTD

Heterobifunctional compounds and their use in treating disease

The invention provides heterobifunctional compounds comprising an effector protein binding moiety selected from mTor, PLK1, CDKI, CDK2, CDK9, BRD4, AURKA, AURKB, MEK, Src, c-KIT, KIF11, HSP90, tubulin, proteasome, topoisomerase or HD AC which is linked to a moiety that binds to a target protein selected from KRAS, HER2 or EGFR. Pharmaceutical compositions and their use in treating disease, such as cancer, are also disclosed.
Owner:HALDA THERAPEUTICS OPCO INC

Multivalent degraders

PCT designated stage expiredWO2024241046A1Organic active ingredientsOrganic chemistryUbiquitin ligaseBRD4
This invention particularly relates to hetero-multivalent PROTACs of formula (I) as described herein which bind to a protein within the Bromo- and Extra-Terminal (BET) family of proteins, and especially to hetero-multivalent PROTACs including different small molecule E3 ubiquitin ligase protein binding ligand compounds, which induce degradation of the BRD2, BRD3 and BRD4 proteins within the bromodomain of the BET family of proteins. (Formula (I).
Owner:UNIVERSITY OF DUNDEE

Enhanced combination immune checkpoint inhibition therapy utilizing rnai

PCT designated stage expiredWO2025117786A1Organic active ingredientsAntibody ingredientsBRD4Double strand
Aspects of the disclosure relate to methods for enhanced combination immune checkpoint inhibition therapy utilizing RNAi, including by intratumoral administration of chemically-modified double stranded nucleic acid molecules directed against genes encoding PD-1, BRD4, CTLA-4, TIGIT, and / or CBL-B.
Owner:PHIO PHARMACEUTICALS CORP

Self-assembly PROTAC nano material based on mitochondria targeting of natural product as well as preparation method and application of self-assembly PROTAC nano material

The invention discloses a self-assembled PROTAC nano material based on natural product mitochondria targeting, which is a nano particle prepared from mitochondria targeting molecules, a photosensitizer and PROTAC as raw materials through a nano precipitation method. The mitochondrial targeting molecule is berberine, the photosensitizer is hypericin, and the PROTAC is dBET57; the ratio of the amount of substance of the dBET57 to the amount of substance of the berberine is (1-10): (1-10), and the ratio of the amount of substance of the dBET57 to the amount of substance of the hypericin is (1-10): (1-10). The nano material can be used for blocking multiple energy metabolism pathways of tumor cells, including glycolysis and oxidative phosphorylation, meanwhile, mitochondria is damaged, ferroptosis is induced, and the anti-tumor capacity of pharmacodynamic molecules is improved; bRD4 in tumor cells and downstream carcinogenic protein c-Myc of the BRD4 can be efficiently degraded. The invention also discloses an application of the nano material in preparation of antitumor drugs.
Owner:FUJIAN UNIV OF TRADITIONAL CHINESE MEDICINE

Degradation agent based on benzimidazole fused covalent warhead as well as preparation method and application of degradation agent

The invention discloses a degradation agent based on benzimidazole fused covalent warheads as well as a preparation method and application of the degradation agent, and relates to the technical field of drug development. The structural formula of the degradation agent based on the benzimidazole fused covalent warhead is shown in the specification, wherein, is phenyl or substituted phenyl; r is methyl or tertiary butyl; the structure is selected from one of the following structures:,,,,,,,,, and; and a connection site is represented. According to the invention, a series of degradation agents based on benzimidazole fused covalent warheads are obtained by utilizing the modular design of a benzimidazole guiding group and an acrylate covalent warhead and then connecting with a BRD4 protein inhibitor JQ1 through a connexon. The degradation agent based on the benzimidazole fused covalent warhead can target the BRD4 protein and efficiently degrade the BRD4 protein. Therefore, targeted degradation of the BRD4 protein is realized while a protein degradation targeted chimera molecular library is enriched.
Owner:SHENZHEN UNIV

Heterobifunctional compound for targeted degradation of BRD4 based on HSP70, preparation and application

The invention provides a hetero-bifunctional compound for targeted degradation of BRD4 based on HSP70, and preparation and application thereof, and belongs to the technical field of pharmaceutical synthesis chemical industry. An HSP70 inhibitor is selected as a ligand part A combined with HSP70, a BRD4 inhibitor is selected as a ligand part B combined with BRD4, and the ligand A of HSP70 and the ligand B of BRD4 are connected through a connecting chain Linker to obtain a series of bifunctional degradation agents capable of degrading BRD4 to different degrees, and the obtained degradation agents have the characteristics of high selectivity and strong activity, and can be used for degrading BRD4 in different degrees. The defects of poor selectivity, strong toxic and side effects and the like of a BRD4 inhibitor on tumor tissues can be overcome.
Owner:CHINA PHARM UNIV

Application of inhibiting N4BP1 based on super enhancer in preparation of medicine for resisting human oral squamous cell carcinoma

The invention provides application of inhibition of N4BP1 in preparation of a medicine for resisting human oral squamous cell carcinoma based on a super enhancer, relates to the technical field of biomedicine, and is technically characterized in that the super enhancer of the N4BP1 is used as a target to inhibit a new way of the function of the N4BP1. The key protein BRD4 of the super enhancer is inhibited to inhibit the N4BP1, so that the N4BP1 is applied to the medicine for treating the oral squamous cell carcinoma with high expression of the N4BP1. Specific verification experiments find that in oral squamous carcinoma cells, N4BP1 is regulated by a super enhancer, is in a high expression state and promotes tumor proliferation. BRD4 is used as an apparent regulation factor of a super enhancer, and shows the same expression trend as N4BP1 in oral squamous cell carcinoma. After the BET inhibitor is used for treatment, the N4BP1 expression in the tumor cells is reduced, and the proliferation of the tumor cells with high N4BP1 expression is obviously inhibited.
Owner:NANTONG UNIV

Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof

Provided is a compound or a pharmaceutically acceptable salt thereof which is superior in an action inducing degradation of BRD4 protein and useful as a therapeutic agent for cancer. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the DESCRIPTION.
Owner:TANABE PHARMA CORP

A BRD4 / PLK1 dual-target small molecule fluorescent probe and its preparation method and application

The present invention discloses a BRD4 / PLK1 dual-target small molecule fluorescent probe and its preparation method and application, belonging to the field of biomedicine technology. The BRD4 / PLK1 dual-target small molecule fluorescent probe provided by the present invention has a structure shown in Formula I or a structure shown in Formula II. It has strong biological activity, high affinity with BRD4 / PLK1 family proteins, and high sensitivity. It can be used as a probe to identify BRD4 family proteins and for research on related physiological, pathological, and related diseases; it can be used for high-throughput screening of BRD4 / PLK1 dual-target inhibitors and their application in anti-tumor aspects; it can also be used for labeling BRD4 / PLK1 family proteins and tumor cells or tissues in which they are highly expressed. The probe of the present invention can be used as a probe to identify BRD4 / PLK1 dual-target proteins and BRD4 / PLK1 dual-target proteins have broad application prospects in physiological, pathological, and related diseases. In addition, the preparation method of the BRD4 / PLK1 dual-target small molecule fluorescent probe provided by the present invention has mild reaction conditions, cheap and readily available raw materials, and simple operation and post-processing.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Marker for predicting prognosis of ovarian cancer and application of marker

PendingCN121856554AIncrease gene transcriptionPromote growth and proliferationDisease diagnosisBRD4Oncology
The invention relates to a marker for predicting the prognosis of ovarian cancer and application thereof, and the marker is used for predicting the prognosis condition of ovarian cancer by detecting any one or more of BRD4, H4K12la and Ube2v1. Compared with the prior art, it is found for the first time that BRD4 can be used as a histone milk acylation transferase to enzymatically modify a histone lysine site H4K12, so that the histone lysine site H4K12 is subjected to milk acylation modification, then gene transcription of Ube2v1 is increased, and proliferation and growth of ovarian cancer cells are promoted. The invention not only discovers that BRD4 can be used as histone milk acylation transferase to play a new function of milk acylation modification, but also clarifies the effect of the BRD4-H4K12la-Ube2v1 pathway in the growth process of the ovarian cancer, and provides a new method for targeted therapy of the ovarian cancer.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Aptamer-based targeted protein degradation molecule and application thereof

The invention provides a target protein degradation molecule based on a nucleic acid aptamer and application thereof, a target protein ligand is the nucleic acid aptamer capable of being combined with a target protein, specifically, BRD4 or IRAK4 is taken as the target protein, and the target protein degradation molecule based on the nucleic acid aptamer capable of degrading the target protein is provided. The molecules show the effect of effectively degrading the target protein in cellular level and in vivo experiments, and have small side effects, so that the molecules have good pharmaceutical activity for diseases caused by overexpression of the target protein.
Owner:PEKING UNIV

Ezh2 and brd4 dual-targeted inhibitors and uses thereof

The application discloses an EZH2 and BRD4 double-target inhibitor and application thereof, wherein the double-target inhibitor is obtained by coupling a structural fragment for inhibiting a BRD4 protein and a structural fragment for inhibiting an EZH2 protein through a linker. The inventors find that the structural fragment for inhibiting the EZH2 protein and the structural fragment for inhibiting the BRD4 protein are restructured, coupled together through the linker, and the length of the linker is adjusted, so that the obtained EZH2 and BRD4 double-target inhibitor has an unexpected anti-tumor effect, the anti-tumor effect is better than that of an individual EZH2 inhibitor or BRD4 inhibitor, and is also better than that of a combination of the two under the same conditions.
Owner:SUN YAT SEN UNIVERSITY CANCER CENTER (CANCER HOSPITAL AFFILIATED TO SUN YAT SEN UNIVERSITY CANCER RESEARCH INSTITUTE OF SUN YAT SEN UNIVERSITY)

Double E3-PROTAC as well as preparation method and application thereof

The invention discloses diE3-PROTAC selected from a compound with a structure as shown in a formula I or pharmaceutically acceptable salt and racemate thereof, n is an integer from 2 to 8, R1 and R2 are respectively and independently selected from X selected from CH2 and C = O, and m is an integer from 2 to 3. The double E3-PROTACs disclosed by the invention have good degradation activity on the BRD4 protein, and the degradation efficiency of the double E3-PROTACs on the BRD4 protein is superior to that of the corresponding traditional PROTACs. The invention also discloses an application of the compound or the pharmaceutically acceptable salt and racemate thereof in preparation of a targeted BRD4 degradation agent. The invention also discloses application of the compound or the pharmaceutically acceptable salt and racemate thereof in preparation of drugs for treating BRD4 protein related diseases.
Owner:WUXI WANGTIAN PHARMACEUTICAL TECHNOLOGY CO LTD

Small molecule bromodomain inhibitors and uses therof

The present invention relates to compounds that bind to and otherwise modulate the activity of bromodomain-containing proteins, including BRD4, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders. In particular, this disclosure provides certain BRD4 inhibitors for the treatment of fibrotic diseases or conditions.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES +1

Method for detecting aortic dissection through peripheral blood BRD4 based on flow cytometry and application

The invention discloses a method for detecting aortic dissection through peripheral blood BRD4 based on flow cytometry and application. The invention belongs to the technical field of biology, and particularly relates to a method for detecting aortic dissection through peripheral blood BRD4 based on flow cytometry and application. The method for detecting the content or expression level of the bromodomain-containing protein 4 in the sample to be detected comprises the following steps: 1) treating the sample to be detected to obtain mononuclear cells; the method comprises the following steps of (1) determining a mononuclear cell, (2) determining a fluorescein coupling antibody composition of a detection index according to a flow cytometry color matching scheme, (3) uniformly mixing the mononuclear cell in the step (1) and the fluorescein coupling antibody in the step (2), incubating in a dark place and dyeing, (4) loading and testing a sample by a spectrum flow cytometry, and (5) analyzing a data result, and the detection indexes in the step (2) are CD45, CD11B, CD66B, CD14, CC16 and BRD4.
Owner:BEIJING INST OF HEART LUNG & BLOOD VESSEL DISEASES

Use of YD-851 in the preparation of a medicament for treating or preventing pulmonary fibrosis

The application discloses a new use of a BET inhibitor YD-851 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis. The application finds that YD-851 can inhibit the expression of BRD4 and fibrosis-related markers in pulmonary fibrosis tissues, reduce the structural damage of bleomycin-induced mouse lung tissues, inflammatory cell infiltration and fibrosis pathological changes, and improve lung function damage. Experimental results show that YD-851 can reduce the pulmonary fibrosis score, inflammation score and area ratio of consolidation, improve the lung imaging abnormalities, and down-regulate the expression of fibrosis-related genes such as Col1a1, Fn1 and Acta2. It is shown that YD-851 has the effect of treating pulmonary fibrosis, and can be used for preparing a drug for treating pulmonary fibrosis, and a new use of YD-851 is developed.
Owner:CHONGQING UNIVERSITY THREE GORGES HOSPITAL

Compositions and methods for treating autoimmune diseases

PCT designated stageWO2026148150A1Immunologic disordersIRF4
Provided herein are compositions and methods for treating an autoimmune disease or disorder in a subject. In some cases, the compositions and methods use chemical inducers of proximity (CIPs). In some cases, the CIPs include a first moiety having specific binding for a BTB domain-containing protein or a transcriptional repressor expressed in B cell subpopulations and a second moiety having specific binding for a modulator of gene regulation. In some cases, the BTB domain-containing protein comprises BCL6. In some cases, the transcriptional repressor expressed in B cell subpopulations is PRDM1 or IRF4. In some cases the modulator of gene regulation comprises BRD4, CDK9, and / or p300.

Fluorescent probe targeting BRD4 protein as well as preparation method and application of fluorescent probe

The invention discloses a fluorescent probe targeting BRD4 protein as well as a preparation method and application of the fluorescent probe. The BRD4 protein targeting fluorescent probe disclosed by the invention can be used for noninvasively quantifying protein degradation induced by PROTACs in vivo and early predicting the cancer treatment effect of PROTACs drugs, and by combining a POIs targeting ligand and an environment-sensitive fluorophore, an ESR signal shows fluorescence correlation with the POIs level, so that the BRD4 protein targeting fluorescent probe can be used for non-invasively quantifying protein degradation induced by PROTACs in vivo and early predicting the cancer treatment effect of PROTACs drugs. Finally, real-time monitoring of various cancer-related treatment proteins can be realized through non-invasive fluorescence imaging.
Owner:SOUTH CHINA UNIV OF TECH

Compositions, systems, and methods for modulating a target gene

Provided is a method of regulating the expression of a target gene in a cell. Aspects of the method include contacting the cell with a compound having a first moiety covalently linked to a second moiety, wherein: (i) the first moiety exhibits specific binding to a first endogenous protein; (ii) the second moiety exhibits specific binding to a second endogenous protein different from the first endogenous protein; (iii) upon contact with the cell, the first endogenous protein and the second endogenous protein spatially complex with each other via the compound to effect a gain of function in the cell, whereby a process that is not normally regulated by either the first endogenous protein or the second endogenous protein is activated. Here, the first moiety targets BCL-6; the second moiety targets any one of an estrogen receptor, an androgen receptor, BRD4 or a cyclin-dependent kinase. TIFF2025517099000355.tif106159
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Heterobifunctional compounds and methods of use thereof

Disclosed herein are heterobifunctional compounds that include a moiety that binds to the Y220C mutant of the p53 protein, a moiety that binds to the effector protein BRD4, and a linker. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., to treat proliferative diseases such as cancers.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Cyclic BRD4 protein degradation agent and application thereof

The invention provides a BRD4 protein degradation agent and application thereof, and particularly provides a compound with a structure as shown in a formula (I) or pharmaceutically acceptable salt thereof, or a stereoisomer or a prodrug molecule thereof. The compound can degrade BRD4 protein in a targeted manner through a ubiquitin-proteasome way, so that the compound can be used for treating indications mediated by abnormal expression of the BRD4 protein. Wherein each group in the formula (I) is defined in the specification.
Owner:SHANGHAI INST OF ORGANIC CHEM CHINESE ACAD OF SCI

Sulfonamide or sulfinamide compound having effect of inducing BRD4 protein degradation and pharmaceutical use thereof

PendingAU2021215623B2BRD4Pharmaceutical medicine
The purpose of the present invention is to provide a compound that has an excellent effect of inducing BRD4 protein degradation and is useful as a cancer therapeutic agent, or a pharmaceutically acceptable salt thereof. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof. [In the formula, each symbol is as defined in the description.]
Owner:TANABE PHARMA CORP

Compounds and methods for modulating frataxin expression

The present technology relates to compositions and methods for modulating expression of genes, which include a target oligonucleotide sequence, such as repeats of a particular oligonucleotide sequence containing 3 to 10 nucleotides. In particular aspects, the present technology relates to agents having a formula A-L-B, wherein -L- is a linker; A- is a Brd4 binding moiety; and —B is a nucleic acid binding moiety, such as a polyamide or complementary oligonucleotide, that specifically binds to the target oligonucleotide sequence.
Owner:WISCONSIN ALUMNI RES FOUND

Pyrimidine derivative and application thereof

The invention provides a pyrimidine derivative and application thereof, and belongs to the field of medicinal chemistry. The pyrimidine derivative is a compound as shown in a formula I, a salt, a stereoisomer, a solvate, a hydrate or a prodrug thereof. The pyrimidine derivative disclosed by the invention has a good inhibition effect on BRD4-BD1 and HDAC1 proteins, can be used as a novel BET-HDAC bifunctional inhibitor, is used for preventing and / or treating various diseases related to BET and HDAC, such as cancers, has an excellent effect, and has a good application prospect.
Owner:CHONGQING UNIV OF ARTS & SCI

BRD4-JAK2 inhibitors

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC